Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer crawled date : 2022 - 06 - 06 save search
New Late-Breaking Data on Investigational Adagrasib Show Regression of Central Nervous System (CNS) Metastases in Patients with KRASG12C-mutated Non-Small Cell Lung Cancer (NSCLC) with Active, Untreated CNS Metastases
Published: 2022-06-06 (Crawled : 19:00) - biospace.com/
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 6.31%
H: 1.07%
C: -2.15%
krasg12 system cancer
Seagen and Genmab Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
Published: 2022-06-06 (Crawled : 15:20) - biospace.com/
GNMSF | $290.38 3.83% 220
|
Health Technology
|
| O: -0.79%
H: 5.87%
C: 0.32%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 1.77%
H: 0.72%
C: 0.08%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: 0.26%
H: 0.34%
C: -1.81%
tivdak research program asco cancer
Genmab and Seagen Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
Published: 2022-06-06 (Crawled : 15:20) - globenewswire.com
GNMSF | $290.38 3.83% 220
|
Health Technology
|
| O: -0.79%
H: 5.87%
C: 0.32%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 1.77%
H: 0.72%
C: 0.08%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: 0.26%
H: 0.34%
C: -1.81%
tivdak research program asco cancer
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting
Published: 2022-06-06 (Crawled : 15:00) - biospace.com/
PBYI | $5.01 0.4% 0.4% 290K
|
Health Technology
|
| O: 0.85%
H: 2.54%
C: 1.27%
trial asco cancer breast cancer metastatic breast cancer
ImmunityBio Announces QUILT Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer at the 2022 American Society of Clinical Oncology Annual Meeting
Published: 2022-06-06 (Crawled : 13:00) - nantkwest.com
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: 0.17%
H: 0.0%
C: 0.0%
IBRX | $5.265 7.23% 6.74% 4.6M
|
Manufacturing
|
| O: 14.42%
H: 1.88%
C: -4.29%
trial cancer pancreatic bladder
Clovis Oncology’s Rubraca® (Rucaparib) as First-Line Maintenance Treatment Significantly Improves Progression-Free Survival in Women with Advanced Ovarian Cancer in Primary Efficacy Analyses Regardless of BRCA Mutation and HRD Status
Published: 2022-06-06 (Crawled : 12:20) - biospace.com/
CLVS | $0.0812 -3.94%
|
Health Technology
|
| O: 15.34%
H: 0.6%
C: -11.11%
rubraca treatment women cancer ovarian cancer
Verastem Oncology Provides Update on RAMP 201 Study Evaluating VS-6766 ± Defactinib in Low-Grade Serous Ovarian Cancer
Published: 2022-06-06 (Crawled : 12:00) - biospace.com/
VSTM | $9.86 -3.62% -3.75% 150K
|
Health Technology
|
| O: 3.05%
H: 0.74%
C: -9.63%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 6.31%
H: 1.07%
C: -2.15%
vs-6766 cancer defactinib ovarian cancer
Landmark Five-Year Data from Phase 3 CheckMate -227 Trial Demonstrate Long-Term, Durable Survival Outcomes with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
Published: 2022-06-06 (Crawled : 12:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 1.03%
H: 0.0%
C: 0.0%
treatment opdivo trial plus cancer phase 3 nivolumab
Intensity Therapeutics, The Ottawa Hospital and The Ontario Institute for Cancer Research Report INT230-6 Demonstrates Tumor Necrosis and Immune Activation in Early Stage Breast Cancers
Published: 2022-06-06 (Crawled : 11:00) - prnewswire.com
INTS | $3.93 3.15% 3.05% 5.1K
|
| Email alert
Add to watchlist
int230 research report cancer breast cancer
Veru Announces Presentation of Final Positive Phase 1b/2 Clinical Trial Results for Sabizabulin in Metastatic Castration Resistant Prostate Cancer at the 2022 American Society of Clinical Oncology Annual Meeting
Published: 2022-06-06 (Crawled : 11:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 3.83%
H: 0.0%
C: 0.0%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 10.2%
H: 0.0%
C: 0.0%
sabizabulin trial presentation positive cancer phase 2b prostate cancer
CStone and Pfizer announce NMPA approval of sugemalimab in patients with unresectable stage III non-small cell lung cancer
Published: 2022-06-06 (Crawled : 05:00) - prnewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 1.12%
H: 0.99%
C: 0.13%
approval cancer
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.